Aurobindo Pharma Share Price in Focus as it Incorporates PT Auro Pharm Indonesia for Manufacturing Operations

Aurobindo Pharma Limited has announced the incorporation of a new entity, PT Auro Pharm Indonesia, as a wholly owned stepdown subsidiary as per the exchange filings.  

This strategic move aims to establish manufacturing operations in Indonesia, marking a significant expansion in Southeast Asia. 

New Incorporation Details 

PT Aurogen Pharma Indonesia, a stepdown subsidiary of Aurobindo Pharma, has successfully incorporated PT Auro Pharm Indonesia. The new entity is located in Indonesia and was officially incorporated on July 1, 2026. Local authorities granted final approval on July 9, 2026. 

The establishment of PT Auro Pharm Indonesia aligns with Aurobindo Pharma's strategic objectives to enhance its manufacturing capabilities within the pharmaceutical industry in Indonesia. The new entity will focus on setting up and undertaking manufacturing operations. 

Financials and Ownership Structure 

The parent group holds 100% ownership of PT Auro Pharm Indonesia. The investment involves a full subscription to the share capital, paid entirely in cash.  

The total initial share capital amounts to IDR 20,00,00,00,000, divided into 2,000 equity shares valued at IDR 10,00,000 each. 

Read More: Havells Partners with Norway's Pixii to Enter India's Battery Energy Storage Market! 

About Aurobindo Pharma  

Aurobindo Pharma is a major Indian multinational pharmaceutical company headquartered in HITEC City, Hyderabad. Founded in 1986, it operates globally in over 150 countries. The company specializes in generic pharmaceuticals, specialty formulations, and active pharmaceutical ingredients (APIs) across therapeutic areas like antibiotics, cardiovascular, and oncology 

Aurobindo Pharma Share Price Performance 

As of July 10, 2026, at 1:32 PM, Aurobindo Pharma share price on NSE was trading at ₹1,565.50, down by 1.38% from the previous closing price. 

Conclusion 

Aurobindo Pharma's incorporation of PT Auro Pharm Indonesia, with an initial capital of IDR 20,00,00,00,000, marks a strategic expansion into Indonesia's pharmaceutical manufacturing sector. The entity is wholly owned by Aurobindo Pharma. 

Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.